Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel DiseaseMarieke J. H. Coenen, H. Akol, Dirk J. de Jong et al.|Gastroenterology|2015Cited by 199
Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry StudyMelek Simsek, Nanne K.H. de Boer, Maarten A.C. Meijssen et al.|Journal of Crohn s and Colitis|2023Cited by 12
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M. Jansen, R Pauwels et al.|Digestive Diseases and Sciences|2024Cited by 2
Su1849: LONG-TERM OUTCOMES OF EXTENDED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVAL FOR PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: 3-YEAR FOLLOW-UP OF THE RANDOMIZED CONTROLLED LADI TRIALLisa M. van Lierop, Frank Hoentjen, F. A. R. Jansen et al.|Gastroenterology|2025Cited by 0
P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trialR Van Linschoten, Frank Hoentjen, Fenna M. Jansen et al.|Journal of Crohn s and Colitis|2023Cited by 0